Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
SRXH Catalyst Timeline
Dated clinical, regulatory and corporate events for SRX Global Inc.
Past FDA Catalysts and PDUFA Decisions
How SRXH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every SRXH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| White David AllanDirector | Buy | 69,732 69,732 held | $0.62 | 07/07/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in SRXH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in SRXH for Q3 2026. | ||||
Ownership Trends
SRXH Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How SRXH ranks across every disease it competes in
SRXH News
SRX Global Provides Update on Engineered T-Cell Strategy Following Pfizer–Starna Licensing Agreement
SRX Global announced updates on its engineered T-cell strategy following Pfizer's $330 million licensing deal with Starna Therapeutics. The company is set to acquire CERo Therapeutics, which is advancing its CER-1236 therapy in a Phase 1/1b trial. Initial results show no dose-limiting toxicities, supporting the therapy's safety profile.
Read more →SRX Global Provides Update on Balance Sheet and Share Buyback
SRX Global Inc. reported a balance sheet update, revealing approximately $34 million in cash and equivalents. The company is actively utilizing a stock repurchase program, allowing for up to 10 million shares to be repurchased. Fiscal year-end results are expected to be reported in early December 2026.
Read more →SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
SRX Global has activated UC Davis as a clinical trial site for the Phase 1 CERTAIN-T study of CER-1236 in hematologic malignancies. This activation aims to enhance patient recruitment and streamline treatment logistics. The study has shown promising safety profiles, with no dose-limiting toxicities reported in the second cohort. The trial has expanded to include additional hematologic conditions.
Read more →SRX Global Commits $2.5 Million to Launch Multi-Strategy Trading Platform in Partnership with 5T Trading, Powered by the EMJX Platform
SRX Global Inc. announced a $2.5 million investment to launch a multi-strategy trading platform in partnership with 5T Trading. The initiative aims to support the next generation of proprietary traders under the leadership of Eric Jackson. This venture is part of SRX's strategy to invest in high-conviction assets and generate long-term shareholder value.
Read more →SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancies
SRX Global has entered a definitive agreement to acquire CERo Therapeutics, enhancing its oncology portfolio. This acquisition aims to expedite the development of CERo's lead candidate, CER-1236, for hematologic malignancies. The deal is anticipated to provide CERo with better access to capital and operational resources.
Read more →SRX Global Commits $1.5 Million to Launch Family of AI-Powered ETFs through its EMJX Platform, Partnering with Kupa AI Co-Founder Andy Kim
SRX Global announced a $1.5 million investment to launch a family of AI-powered ETFs via its EMJX platform. The first ETF will focus on actively managing digital asset volatility and is expected to be available in Q1 2027. The company plans to dividend ETF holdings directly to shareholders, enhancing shareholder value.
Read more →SRX Global Provides Shareholders with Update on Liquidation of Two Portfolio Investments and Adds an Investment in Onconetix (Nasdaq: ONCO)
SRX Global Inc. announced an update on its portfolio, liquidating holdings in Vistagen Therapeutics and Greenland Mines. The company has invested in Onconetix, which is set to acquire Realbotix LLC. The Vinci AI Vision system from Realbotix is noted for its innovative technology in robotics.
Read more →SRX Global CEO Kent Cunningham and President of EMJX Platform Eric Jackson to Present at Webull Corporate Connect Series Fintech Investment Webinar
SRX Global Inc. will have its CEO Kent Cunningham and President Eric Jackson present at the Webull Corporate Connect Series Fintech Investment Webinar on September 30, 2026. The webinar aims to engage investors and discuss the company's strategic focus on long-term shareholder value through AI-driven investments. Registration is available on the Webull platform.
Read more →SRX Global Provides Shareholder Update on Portfolio Company, ARMR Sciences, a Clinical-Stage Biodefense Company
SRX Global Inc. provided a shareholder update on its portfolio company ARMR Sciences, highlighting the successful immune response generated by ARMR-100 against fentanyl in clinical trials. The company also announced a contract with the Department of War to develop medical countermeasures and received FDA acceptance into the Model Informed Drug Development program. These developments indicate strong progress and regulatory momentum for ARMR's initiatives.
Read more →SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
SRX Global has acquired senior secured debt in CERo Therapeutics to support the development of CER-1236, an innovative treatment for hematologic cancers. This investment aims to enhance CERo's clinical programs, particularly the ongoing Phase 1 CERTAIN-T trial. The trial has shown promising results, with no dose-limiting toxicities reported.
Read more →SRX Global Inc. Announces Fiscal Third Quarter 2026 Financial Results
SRX Global Inc. reported its fiscal third quarter 2026 results, revealing a 27% increase in net sales to $3.4 million. The adjusted EBITDA loss improved by 35% year over year, and the company ended the quarter with $36.7 million in cash and no debt. Additionally, SRX completed the acquisition of EMJX, enhancing its investment strategy.
Read more →SRX Global to Host Fiscal Third Quarter 2026 Conference Call on August 13 at 4:30 p.m. ET
SRX Global Inc. announced its upcoming conference call to discuss financial results for the fiscal third quarter ending June 30, 2026. The call is scheduled for August 13, 2026, at 4:30 p.m. ET. Interested parties can access a recording on the investor relations website, and a Q&A session will follow the presentation.
Read more →SRX Global Acquires Shares in Jersey Mike’s $1 Billion Initial Public Offering
SRX Global Inc. has announced its acquisition of shares in the initial public offering of Jersey Mike's, which is valued at $1 billion. The IPO priced its Class A common shares at $23.00 each and began trading on the NYSE under the ticker JMKE. SRX Global aims to generate long-term shareholder value through strategic investments.
Read more →SRX Global Board of Directors Authorizes Stock Repurchase Plan of Up to 10 Million Shares or Up to 50% of its Shares Outstanding
SRX Global Inc. has authorized a share repurchase program allowing for the buyback of up to 10 million shares, representing 50% of its outstanding shares. The company plans to allocate $20 million for this initiative, which reflects its strong cash position and confidence in its long-term strategy. The repurchase may occur through various methods, depending on market conditions.
Read more →SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines
SRX Global, Inc. has announced a strategic investment in Greenland Mines Ltd., a company focused on critical and precious minerals development in Greenland. This investment aims to enhance SRX's portfolio and support the development of a multi-asset platform that includes rare earth materials and precious metals. Greenland Mines is working towards linking Greenland's resources with industrial infrastructure in allied jurisdictions.
Read more →SRX Global Announces Share Consolidation
SRX Global, Inc. announced a 60-to-1 share consolidation effective July 6, 2026. This move is expected to streamline the company's stock structure and enhance shareholder value. The common stock will continue to trade under the symbol 'SRXH' and will adopt a new CUSIP number. Shareholders will receive whole shares in lieu of any fractional shares.
Read more →SRX Global Makes Strategic Investment in Clinical-Stage Biodefense Company, ARMR Sciences
SRX Global has made a strategic investment in ARMR Sciences, a clinical-stage company focused on developing medical countermeasures against synthetic drugs like fentanyl. ARMR's lead product, ARMR-100, has shown success in generating an anti-fentanyl immune response in humans. The next phase of trials is set to evaluate its effectiveness against fentanyl, aiming for a long-lasting preventive solution.
Read more →SRx Health Solutions Closes EMJX Acquisition and Launches AI-Driven Platform Strategy Under New Name and Brand, SRX Global, Focused on Investments in High-Conviction Operating Companies and Assets
SRx Health Solutions has completed the acquisition of EMJ Crypto Technologies, rebranding as SRX Global. The company will focus on an AI-driven strategy for capital allocation into high-potential assets. CEO Kent Cunningham emphasized the synergies between the two firms, aiming to enhance shareholder returns. The stock will continue trading under the ticker SRXH.
Read more →SRx Health Solutions Acquires 4.99% of Smartkem, Inc. (NASDAQ: SMTK)
SRx Health Solutions has acquired a 4.99% stake in Smartkem, Inc. as part of a strategic investment. This acquisition was made through a shelf take down and includes the purchase of convertible preferred securities. The company has filed a Registration Statement with the SEC related to this transaction, which will provide further details to shareholders.
Read more →SRx Health Solutions Invests in Uber Technologies, Inc. and Provides Shareholders with Portfolio Update
SRx Health Solutions has updated its portfolio, initiating an investment in Uber Technologies, Inc. The company has also reduced its long position in Compass and trimmed its short exposure to Bitcoin, reflecting a cautious approach due to a shift in their EMJX stress model to STRESS. This marks the first negative market reading since the bull rotation began in April 2026.
Read more →